Thomas Woiwode, PhD

Tom Woiwode, Ph.D., has been working with Versant since 2002, and has served in both operational and investment roles during that time. Tom was the start-up CBO for Amira ($475M sale), Synosia (merged with Biotie, $363M sale) and Flexion (2014 IPO) and was most recently the COO of Okairos where he led the process that culminated in the acquisition by GSK ($325M sale). Since being promoted to Managing Director in 2014, Tom has led several investments including Audentes (2016 IPO), Annapurna (merged to form Adverum), Gritstone (2018 IPO), Crinetics (2018 IPO), Anokion, Therachon, Vividion and Tempest.

Prior to joining Versant, Tom was a medicinal chemist at XenoPort, a start-up biotech company that completed an IPO in 2005. Tom earned his Ph.D. in Chemistry from Stanford University.


Cristina LeClerc


Being a native Californian and surfer, you can often find Tom at the nearest beach trying to catch the next great wave. Tom resides in Basel, Switzerland with his wife and two daughters. Collectively as a family, with Europe as their backyard, they enjoy traveling the world together in search for Tom’s perfect wave.